Quest Diagnostics…
USUSDQuest Diagnostics Incorporated (US:DGX) — Medical Specialities. Biržu skaits, kurās tiek tirgotas uzņēmuma akcijas: 2. Šajā lapā — cena un grafiks, dividendes, lielākie akcionāri un akciju skaita vēsture.
Par uzņēmumu
- Tīmekļvietne
- questdiagnostics.com
- Investoru attiecības
- ir.questdiagnostics.com/overview/default.aspx
- Nozare
- Health Care · Medical Specialities
- Galvenā mītne
- Madison, United States
- Izpilddirektors
- Steve Rusckowski
- Darbinieki
- 46 000
- Dibināts
- 1967
- Apgrozībā esošās akcijas
- 110.37 milj. uz 2026-07-15
- Brīvā apgrozība
- 109.81 milj.
- Tirgus kapitalizācija
- 25.21 mljrd. USD
- Iekšējās personas
- 0.43%
- Institucionālie investori
- 98.9%
- Nozare (SIC)
- Services-Medical Laboratories
- LEI
- 8MCWUBXQ0WE04KMXBX50
- Izmaksas koeficients
- 34.2%
- FCF
- 1.35 mljrd. USD27%
- Parāds
- 5.64 mljrd. USD3.7 g. FCF
- Dividenžu stāžs
- 22 g.
- Peļņa, FCF un izmaksātās dividendes — par 12 mēnešiem līdz 30.06.2026 (uzņēmuma jaunākais ziņojums).
Apraksts
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Dividendes
Quest Diagnostics Incorporated (DGX) izmaksā dividendes reizi ceturksnī. Per year (12 months up to and including the latest announced payment): 3.38 USD per share (payments: 4). Tas ir aptuveni 1.46% no pašreizējās akciju cenas. Pamatojoties uz maksājumu vēsturi, nākamais ex-dividendes datums tiek gaidīts ap 05.01.2027. Nepārtrauktu dividenžu gadi: 22.
| Ex-datums | Izmaksa | Summa | % | Veids | Tikeris |
|---|---|---|---|---|---|
| 2026-10-06 | 2026-10-21 | 0.8600 USD | 0.4/1.5 % | ceturkšņa | US:DGX |
| 2026-07-08 | 2026-07-22 | 0.8600 USD | 0.4/1.4 % | ceturkšņa | US:DGX |
| 2026-04-06 | 2026-04-20 | 0.8600 USD | 0.4/1.4 % | ceturkšņa | US:DGX |
| 2026-01-13 | 2026-01-28 | 0.8000 USD | 0.3/1.4 % | ceturkšņa | US:DGX |
| 2025-10-03 | 2025-10-20 | 0.8000 USD | 0.3/1.4 % | ceturkšņa | US:DGX |
| 2025-07-07 | 2025-07-21 | 0.8000 USD | 0.3/1.3 % | ceturkšņa | US:DGX |
| 2025-04-07 | 2025-04-21 | 0.8000 USD | 0.3/1.3 % | ceturkšņa | US:DGX |
| 2025-01-14 | 2025-01-29 | 0.7500 USD | 0.3/≈1.3 % | ceturkšņa | US:DGX |
| 2024-10-04 | 2024-10-21 | 0.7500 USD | 0.3/≈1.3 % | ceturkšņa | US:DGX |
| 2024-07-08 | 2024-07-22 | 0.7500 USD | 0.3/≈1.3 % | ceturkšņa | US:DGX |
Lielākie akcionāri
| Turētājs | Daļa | Akcijas | Pārskata datums |
|---|---|---|---|
| Blackrock Inc. | 8.4% | 9.28 milj. | 2026-06-30 |
| Vanguard Capital Managem… | 6.55% | 7.23 milj. | 2026-06-30 |
| Vanguard Portfolio Manag… | 5.55% | 6.13 milj. | 2026-06-30 |
| State Street Corporation | 5% | 5.52 milj. | 2026-06-30 |
| Price (T.Rowe) Associate… | 4.93% | 5.44 milj. | 2026-06-30 |
| Boston Partners | 4.3% | 4.74 milj. | 2026-06-30 |
| JPMORGAN CHASE & CO | 3.19% | 3.52 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.18% | 3.51 milj. | 2026-06-30 |
| Geode Capital Management… | 2.84% | 3.14 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.6% | 2.87 milj. | 2026-06-30 |
| Morgan Stanley | 2.23% | 2.46 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.17% | 2.4 milj. | 2026-06-30 |
| Edgepoint Investment Gro… | 2.04% | 2.25 milj. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.33% | 1.47 milj. | 2026-08-31 |
| Fidelity Concord Street… | 1.3% | 1.43 milj. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.23% | 1.36 milj. | 2026-08-31 |
| John Hancock Funds III-D… | 1.09% | 1.2 milj. | 2026-07-31 |
| JPMorgan Trust II-JPMorg… | 1.04% | 1.15 milj. | 2026-06-30 |
| T. Rowe Price Dividend G… | 1% | 1.11 milj. | 2026-06-30 |
| John Hancock Funds III-D… | 0.96% | 1.06 milj. | 2026-07-31 |
| DAVIS J E CAUSEY (Chief… | ≈0.13% | 142 423 | 2026-03-04 |
| DAVIS JAMES E (Chief Exe… | ≈0.11% | 122 423 | 2026-09-01 |
| DOHERTY CATHERINE T (Off… | ≈0.06% | 71 624 | 2026-03-05 |
| PREVOZNIK MICHAEL E (Gen… | ≈0.04% | 42 337 | 2026-08-28 |
| DEPPE MICHAEL J (Officer… | ≈0.03% | 35 196 | 2026-03-04 |
| SAMAD SAMER ABDUL (Chief… | ≈0.03% | 33 478 | 2026-07-22 |
| RING TIMOTHY M (Director… | ≈0.03% | 31 140 | 2026-05-20 |
| PFEIFFER GARY M (Directo… | ≈0.03% | 31 005 | 2026-05-20 |
| MAIN TIMOTHY L (Director… | ≈0.02% | 27 460 | 2026-07-22 |
| GREGG VICKY B (Director) | ≈0.02% | 18 386 | 2026-07-22 |
Pieslēdzies ar Google